Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
A list of letters sent to healthcare professionals in April 2007, to inform of new safety information and advice.
| Date issued | Product | Safety information |
|---|---|---|
| 02/04/2007 | Mabthera (rituximab) | Reports of progressive multifocal leukoencephalopathy in unapproved indications of systemic lupus erythematosus and vasculitis |
| 11/04/2007 | Pioglitazone-containing products (Actos, Glustin, Competact, Tandemact) | Risk of fractures in women on long-term treatment |
| 12/04/2007 | Cabaser (cabergoline) | Pathological gambling and increased libido are potential class effects of dopamine agonists Risk of fibrotic cardiac valvuopathy: important information about second-line indication, contraindications, and new monitoring requirements |
| 16/04/2007 | Desmopressin | Removal of primary nocturnal enuresis indication |
| 17/04/2007 | Ketek (telithromycin) | Important information about restricted indications, contraindications, and safety measures |
| 27/04/2007 | Ventolin (salbutamol) | New prescribing advice for obstetric use in the management of preterm labour and for use in respiratory disease |
